

Anthony Wing-Hung Chan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3243478/publications.pdf>

Version: 2024-02-01

406
papers

27,821
citations

3325

91
h-index

7931

149
g-index

415
all docs

415
docs citations

415
times ranked

25832
citing authors

#	ARTICLE	IF	CITATIONS
1	Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. <i>Hepatology</i> , 2010, 51, 454-462.	3.6	1,052
2	Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. <i>Gut</i> , 2010, 59, 969-974.	6.1	538
3	Clinical Scoring System to Predict Hepatocellular Carcinoma in Chronic Hepatitis B Carriers. <i>Journal of Clinical Oncology</i> , 2010, 28, 1660-1665.	0.8	424
4	Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography. <i>Gut</i> , 2012, 61, 409-415.	6.1	423
5	Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients With liver cirrhosis. <i>Hepatology</i> , 2013, 58, 1537-1547.	3.6	408
6	Risk of hepatocellular carcinoma in chronic hepatitis B: Assessment and modification with current antiviral therapy. <i>Journal of Hepatology</i> , 2015, 62, 956-967.	1.8	398
7	Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study. <i>Gut</i> , 2016, 65, 1359-1368.	6.1	386
8	Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites. <i>Gut</i> , 2021, 70, 761-774.	6.1	382
9	Alanine aminotransferase-based algorithms of liver stiffness measurement by transient elastography (Fibroscan) for liver fibrosis in chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2009, 16, 36-44.	1.0	363
10	Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection. <i>Journal of Hepatology</i> , 2018, 69, 1284-1293.	1.8	360
11	Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017 Part 1: Definition, risk factors and assessment. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 70-85.	1.4	358
12	<i>MET</i> Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non-small Cell Lung Carcinoma with Poor Prognosis. <i>Clinical Cancer Research</i> , 2016, 22, 3048-3056.	3.2	352
13	RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	343
14	Serum Hepatitis B Surface Antigen Quantitation Can Reflect Hepatitis B Virus in the Liver and Predict Treatment Response. <i>Clinical Gastroenterology and Hepatology</i> , 2007, 5, 1462-1468.	2.4	320
15	<i>Peptostreptococcus anaerobius</i> Induces Intracellular Cholesterol Biosynthesis in Colon Cells to Induce Proliferation and Causes Dysplasia in Mice. <i>Gastroenterology</i> , 2017, 152, 1419-1433.e5.	0.6	308
16	Liver Stiffness Measurement Using XL Probe in Patients With Nonalcoholic Fatty Liver Disease. <i>American Journal of Gastroenterology</i> , 2012, 107, 1862-1871.	0.2	292
17	<i>Peptostreptococcus anaerobius</i> promotes colorectal carcinogenesis and modulates tumour immunity. <i>Nature Microbiology</i> , 2019, 4, 2319-2330.	5.9	281
18	Hepatitis B surface antigen quantification: Why and how to use it in 2011 – A core group report. <i>Journal of Hepatology</i> , 2011, 55, 1121-1131.	1.8	280

#	ARTICLE	IF	CITATIONS
19	High Viral Load and Hepatitis B Virus Subgenotype Ce Are Associated With Increased Risk of Hepatocellular Carcinoma. <i>Journal of Clinical Oncology</i> , 2008, 26, 177-182.	0.8	278
20	Quantitative Elastography of Liver Fibrosis and Spleen Stiffness in Chronic Hepatitis B Carriers: Comparison of Shear-Wave Elastography and Transient Elastography with Liver Biopsy Correlation. <i>Radiology</i> , 2013, 269, 910-918.	3.6	267
21	The role of quantitative hepatitis B surface antigen revisited. <i>Journal of Hepatology</i> , 2017, 66, 398-411.	1.8	267
22	Molecular Characterization of the Fecal Microbiota in Patients with Nonalcoholic Steatohepatitis "A Longitudinal Study. <i>PLoS ONE</i> , 2013, 8, e62885.	1.1	266
23	Histological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patients. <i>Hepatology</i> , 2017, 65, 54-64.	3.6	260
24	Community-based lifestyle modification programme for non-alcoholic fatty liver disease: A randomized controlled trial. <i>Journal of Hepatology</i> , 2013, 59, 536-542.	1.8	254
25	Viral-Human Chimeric Transcript Predisposes Risk to Liver Cancer Development and Progression. <i>Cancer Cell</i> , 2014, 25, 335-349.	7.7	254
26	Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study. <i>Annals of Hepatology</i> , 2013, 12, 256-262.	0.6	252
27	A Randomized, Controlled Trial of Combination Therapy for Chronic Hepatitis B: Comparing Pegylated Interferon- α 2b and Lamivudine with Lamivudine Alone. <i>Annals of Internal Medicine</i> , 2005, 142, 240.	2.0	248
28	Coronary artery disease and cardiovascular outcomes in patients with non-alcoholic fatty liver disease. <i>Gut</i> , 2011, 60, 1721-1727.	6.1	248
29	Prevalence and Severity of Nonalcoholic Fatty Liver Disease in Non-Obese Patients: A Population Study Using Proton-Magnetic Resonance Spectroscopy. <i>American Journal of Gastroenterology</i> , 2015, 110, 1306-1314.	0.2	240
30	Liver stiffness-based optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2014, 60, 339-345.	1.8	227
31	Exome and genome sequencing of nasopharynx cancer identifies NF- κ B pathway activating mutations. <i>Nature Communications</i> , 2017, 8, 14121.	5.8	227
32	A longitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic hepatitis B. <i>Hepatology</i> , 2010, 52, 1232-1241.	3.6	226
33	Yes-Associated Protein 1 Exhibits Oncogenic Property in Gastric Cancer and Its Nuclear Accumulation Associates with Poor Prognosis. <i>Clinical Cancer Research</i> , 2011, 17, 2130-2139.	3.2	224
34	MiR-222 Overexpression Confers Cell Migratory Advantages in Hepatocellular Carcinoma through Enhancing AKT Signaling. <i>Clinical Cancer Research</i> , 2010, 16, 867-875.	3.2	221
35	High prevalence of colorectal neoplasm in patients with non-alcoholic steatohepatitis. <i>Gut</i> , 2011, 60, 829-836.	6.1	219
36	Diagnosis of liver fibrosis and cirrhosis using liver stiffness measurement: Comparison between M and XL probe of FibroScan $\text{\textcircled{R}}$. <i>Journal of Hepatology</i> , 2012, 56, 833-839.	1.8	218

#	ARTICLE	IF	CITATIONS
37	Prognostic Nutritional Index (PNI) Predicts Tumor Recurrence of Very Early/Early Stage Hepatocellular Carcinoma After Surgical Resection. <i>Annals of Surgical Oncology</i> , 2015, 22, 4138-4148.	0.7	206
38	Identification of Chronic Hepatitis B Patients without Significant Liver Fibrosis by a Simple Noninvasive Predictive Model. <i>American Journal of Gastroenterology</i> , 2005, 100, 616-623.	0.2	200
39	Hepatocellular Carcinoma and Hepatitis B Virus. <i>Seminars in Liver Disease</i> , 2006, 26, 153-161.	1.8	198
40	Metabolic syndrome increases the risk of liver cirrhosis in chronic hepatitis B. <i>Gut</i> , 2009, 58, 111-117.	6.1	198
41	Non-invasive diagnosis of non-alcoholic steatohepatitis by combined serum biomarkers. <i>Journal of Hepatology</i> , 2012, 56, 1363-1370.	1.8	198
42	Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2018, 69, 1349-1356.	1.8	198
43	High serum interleukin-6 level predicts future hepatocellular carcinoma development in patients with chronic hepatitis B. <i>International Journal of Cancer</i> , 2009, 124, 2766-2770.	2.3	197
44	Hepatitis B virus infection and fatty liver in the general population. <i>Journal of Hepatology</i> , 2012, 56, 533-540.	1.8	196
45	Fatty Pancreas, Insulin Resistance, and β^2 -Cell Function: A Population Study Using Fat-Water Magnetic Resonance Imaging. <i>American Journal of Gastroenterology</i> , 2014, 109, 589-597.	0.2	194
46	Sirtuin 1 Is Upregulated in a Subset of Hepatocellular Carcinomas where It Is Essential for Telomere Maintenance and Tumor Cell Growth. <i>Cancer Research</i> , 2011, 71, 4138-4149.	0.4	189
47	Metabolic and Adipokine Profile of Chinese Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2006, 4, 1154-1161.	2.4	181
48	SIRT2 overexpression in hepatocellular carcinoma mediates epithelial to mesenchymal transition by protein kinase B/glycogen synthase kinase-3 β / β -catenin signaling. <i>Hepatology</i> , 2013, 57, 2287-2298.	3.6	179
49	Improved noninvasive prediction of liver fibrosis by liver stiffness measurement in patients with nonalcoholic fatty liver disease accounting for controlled attenuation parameter values. <i>Hepatology</i> , 2017, 65, 1145-1155.	3.6	177
50	Modulation of LMP2A Expression by a Newly Identified Epstein-Barr Virus-Encoded MicroRNA miR-BART22. <i>Neoplasia</i> , 2009, 11, 1174-1177.	2.3	176
51	HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues. <i>Journal of Hepatology</i> , 2019, 70, 361-370.	1.8	173
52	Epigenetic Therapy Using Belinostat for Patients With Unresectable Hepatocellular Carcinoma: A Multicenter Phase I/II Study With Biomarker and Pharmacokinetic Analysis of Tumors From Patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group. <i>Journal of Clinical Oncology</i> , 2012, 30, 3361-3367.	0.8	167
53	Deep sequencing of small RNA transcriptome reveals novel non-coding RNAs in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2013, 58, 1165-1173.	1.8	160
54	Tenofovir Is Associated With Lower Risk of Hepatocellular Carcinoma Than Entecavir in Patients With Chronic HBV Infection in China. <i>Gastroenterology</i> , 2020, 158, 215-225.e6.	0.6	156

#	ARTICLE	IF	CITATIONS
55	Pathogenesis and novel treatment options for non-alcoholic steatohepatitis. <i>The Lancet Gastroenterology and Hepatology</i> , 2016, 1, 56-67.	3.7	152
56	Concurrent fatty liver increases risk of hepatocellular carcinoma among patients with chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 667-676.	1.4	152
57	Controlled attenuation parameter for the diagnosis of steatosis in non-alcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 848-855.	1.4	151
58	Long-term impact of liver function on curative therapy for hepatocellular carcinoma: application of the ALBI grade. <i>British Journal of Cancer</i> , 2016, 114, 744-750.	2.9	150
59	Incidence of non-alcoholic fatty liver disease in Hong Kong: A population study with paired proton-magnetic resonance spectroscopy. <i>Journal of Hepatology</i> , 2015, 62, 182-189.	1.8	147
60	Assessment of Fibrosis by Transient Elastography Compared With Liver Biopsy and Morphometry in Chronic Liver Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2008, 6, 1027-1035.	2.4	143
61	Management of hepatocellular carcinoma with portal vein tumor thrombosis: Review and update at 2016. <i>World Journal of Gastroenterology</i> , 2016, 22, 7289.	1.4	138
62	Hepatoma-intrinsic CCRK inhibition diminishes myeloid-derived suppressor cell immunosuppression and enhances immune-checkpoint blockade efficacy. <i>Gut</i> , 2018, 67, 931-944.	6.1	138
63	Interchangeability of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy. <i>Modern Pathology</i> , 2020, 33, 4-17.	2.9	135
64	Serial combination of non-invasive tools improves the diagnostic accuracy of severe liver fibrosis in patients with NAFLD. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 617-627.	1.9	134
65	Viral genotype and hepatitis B virus DNA levels are correlated with histological liver damage in HBeAg-negative chronic hepatitis B virus infection. <i>American Journal of Gastroenterology</i> , 2002, 97, 406-412.	0.2	131
66	Hepatitis B Virus Genotype C Takes a More Aggressive Disease Course Than Hepatitis B Virus Genotype B in Hepatitis B e Antigen-Positive Patients. <i>Journal of Clinical Microbiology</i> , 2003, 41, 1277-1279.	1.8	127
67	PNPLA3 gene polymorphism and response to lifestyle modification in patients with nonalcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 139-146.	1.4	125
68	miR-375 is involved in Hippo pathway by targeting YAP1/TEAD4-CTGF axis in gastric carcinogenesis. <i>Cell Death and Disease</i> , 2018, 9, 92.	2.7	125
69	Genomic and Epigenomic Features of Primary and Recurrent Hepatocellular Carcinomas. <i>Gastroenterology</i> , 2019, 157, 1630-1645.e6.	0.6	123
70	Liver injury is independently associated with adverse clinical outcomes in patients with COVID-19. <i>Gut</i> , 2021, 70, 733-742.	6.1	121
71	Impact of the New Definition of Metabolic Associated Fatty Liver Disease on the Epidemiology of the Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2161-2171.e5.	2.4	119
72	Renal Outcome in Type 2 Diabetic Patients With or Without Coexisting Nondiabetic Nephropathies. <i>Diabetes Care</i> , 2002, 25, 900-905.	4.3	118

#	ARTICLE	IF	CITATIONS
73	The Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017 Part 2: Management and special groups. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 86-98.	1.4	117
74	Targeting monocyte-intrinsic enhancer reprogramming improves immunotherapy efficacy in hepatocellular carcinoma. <i>Gut</i> , 2020, 69, 365-379.	6.1	117
75	Wnt/ β -Catenin activates MiR-183/96/182 expression in hepatocellular carcinoma that promotes cell invasion. <i>Cancer Letters</i> , 2015, 362, 97-105.	3.2	114
76	Coincidental metabolic syndrome increases the risk of liver fibrosis progression in patients with chronic hepatitis B – a prospective cohort study with paired transient elastography examinations. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 883-893.	1.9	113
77	Unified interpretation of liver stiffness measurement by M and XL probes in non-alcoholic fatty liver disease. <i>Gut</i> , 2019, 68, 2057-2064.	6.1	113
78	Impact of age and gender on risk of hepatocellular carcinoma after hepatitis B surface antigen seroclearance. <i>Journal of Hepatology</i> , 2017, 67, 902-908.	1.8	112
79	Development of a non-invasive algorithm with transient elastography (Fibroscan) and serum test formula for advanced liver fibrosis in chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 31, 1095-1103.	1.9	110
80	Viral Determinants of Hepatitis B Surface Antigen Seroclearance in Hepatitis B e Antigen-Negative Chronic Hepatitis B Patients. <i>Journal of Infectious Diseases</i> , 2011, 204, 408-414.	1.9	110
81	Validity criteria for the diagnosis of fatty liver by M probe-based controlled attenuation parameter. <i>Journal of Hepatology</i> , 2017, 67, 577-584.	1.8	110
82	Metabolic and histological features of non-alcoholic fatty liver disease patients with different serum alanine aminotransferase levels. <i>Alimentary Pharmacology and Therapeutics</i> , 2009, 29, 387-396.	1.9	108
83	Increased liver stiffness measurement by transient elastography in severe acute exacerbation of chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009, 24, 1002-1007.	1.4	104
84	Integration of albumin-bilirubin (ALBI) score into Barcelona Clinic Liver Cancer (BCLC) system for hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 1300-1306.	1.4	103
85	Validation of the NAFLD Fibrosis Score in a Chinese Population With Low Prevalence of Advanced Fibrosis. <i>American Journal of Gastroenterology</i> , 2008, 103, ???-???	0.2	101
86	Long-term clinical outcomes after fatty liver screening in patients undergoing coronary angiogram: A prospective cohort study. <i>Hepatology</i> , 2016, 63, 754-763.	3.6	101
87	Durability of peginterferon alfa-2b treatment at 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. <i>Hepatology</i> , 2010, 51, 1945-1953.	3.6	100
88	Frequent hypermethylation of promoter region of RASSF1A in tumor tissues and voided urine of urinary bladder cancer patients. <i>International Journal of Cancer</i> , 2003, 104, 611-616.	2.3	97
89	Liver Stiffness Measurement by Transient Elastography as a Predictor on Posthepatectomy Outcomes. <i>Annals of Surgery</i> , 2013, 257, 922-928.	2.1	96
90	Phase I/II study of tamsirolimus for patients with unresectable Hepatocellular Carcinoma (HCC)- a correlative study to explore potential biomarkers for response. <i>BMC Cancer</i> , 2015, 15, 395.	1.1	96

#	ARTICLE	IF	CITATIONS
91	<i>PNPLA3</i> gene polymorphism accounts for fatty liver in community subjects without metabolic syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 532-539.	1.9	95
92	New simple prognostic score for primary biliary cirrhosis: Albumin-bilirubin score. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 1391-1396.	1.4	95
93	Prediction of Survival Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma: A Response-Based Approach. <i>Hepatology</i> , 2020, 72, 198-212.	3.6	92
94	Prevalence of undiagnosed diabetes and postchallenge hyperglycaemia in Chinese patients with non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 24, 1215-1222.	1.9	88
95	Epigenetic regulation of hepatocellular carcinoma in non-alcoholic fatty liver disease. <i>Seminars in Cancer Biology</i> , 2013, 23, 471-482.	4.3	88
96	MiR-145 modulates multiple components of the insulin-like growth factor pathway in hepatocellular carcinoma. <i>Carcinogenesis</i> , 2012, 33, 1134-1141.	1.3	84
97	Evaluation of Alanine Transaminase and Hepatitis B Virus DNA to Predict Liver Cirrhosis in Hepatitis B e Antigen-Negative Chronic Hepatitis B Using Transient Elastography. <i>American Journal of Gastroenterology</i> , 2008, 103, 3071-3081.	0.2	83
98	Albumin-to-Alkaline Phosphatase Ratio: A Novel Prognostic Index for Hepatocellular Carcinoma. <i>Disease Markers</i> , 2015, 2015, 1-10.	0.6	83
99	Statin and the risk of hepatocellular carcinoma and death in a hospital-based hepatitis B-infected population: A propensity score landmark analysis. <i>Journal of Hepatology</i> , 2015, 63, 1190-1197.	1.8	83
100	Transient elastography. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010, 25, 1726-1731.	1.4	82
101	On-Treatment Monitoring of Liver Fibrosis with Transient Elastography in Chronic Hepatitis B Patients. <i>Antiviral Therapy</i> , 2011, 16, 165-172.	0.6	82
102	Management of patients with liver derangement during the COVID-19 pandemic: an Asia-Pacific position statement. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 776-787.	3.7	82
103	Stathmin1 Plays Oncogenic Role and Is a Target of MicroRNA-223 in Gastric Cancer. <i>PLoS ONE</i> , 2012, 7, e33919.	1.1	82
104	Factors associated with viral breakthrough in lamivudine monotherapy of hepatitis B virus recurrence after liver transplantation. <i>Journal of Medical Virology</i> , 2002, 68, 182-187.	2.5	81
105	A Randomized, Open-Label Clinical Study of Combined Pegylated Interferon Alfa-2a (40KD) and Entecavir Treatment for Hepatitis B "e" Antigen-Positive Chronic Hepatitis B. <i>Clinical Infectious Diseases</i> , 2014, 59, 1714-1723.	2.9	79
106	Normal on-treatment ALT during antiviral treatment is associated with a lower risk of hepatic events in patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2018, 69, 793-802.	1.8	79
107	Long-term follow-up of peginterferon and lamivudine combination treatment in HBeAg-positive chronic hepatitis B. <i>Hepatology</i> , 2005, 41, 1357-1364.	3.6	77
108	Durability of hepatitis B surface antigen seroclearance in untreated and nucleos(t)ide analogue-treated patients. <i>Journal of Hepatology</i> , 2018, 68, 63-72.	1.8	77

#	ARTICLE	IF	CITATIONS
109	Diet-Quality Scores and Prevalence of Nonalcoholic Fatty Liver Disease: A Population Study Using Proton-Magnetic Resonance Spectroscopy. <i>PLoS ONE</i> , 2015, 10, e0139310.	1.1	77
110	Two-year Lamivudine treatment for Hepatitis B e Antigen-Negative Chronic Hepatitis B: A Double-Blind, Placebo-Controlled Trial. <i>Antiviral Therapy</i> , 2007, 12, 345-354.	0.6	76
111	Hepatitis B Virus Genotype C Is Associated With More Severe Liver Fibrosis Than Genotype B. <i>Clinical Gastroenterology and Hepatology</i> , 2009, 7, 1361-1366.	2.4	75
112	A novel interplay between oncogenic PFTK1 protein kinase and tumor suppressor TAGLN2 in the control of liver cancer cell motility. <i>Oncogene</i> , 2011, 30, 4464-4475.	2.6	75
113	Expression of stemness markers (CD133 and EpCAM) in prognostication of hepatocellular carcinoma. <i>Histopathology</i> , 2014, 64, 935-950.	1.6	75
114	Liver stiffness measurement predicts long-term survival and complications in non-alcoholic fatty liver disease. <i>Liver International</i> , 2020, 40, 581-589.	1.9	75
115	Carboxyl-Terminal Truncated HBx Regulates a Distinct MicroRNA Transcription Program in Hepatocellular Carcinoma Development. <i>PLoS ONE</i> , 2011, 6, e22888.	1.1	73
116	Advanced liver fibrosis but not steatosis is independently associated with albuminuria in Chinese patients with type 2 diabetes. <i>Journal of Hepatology</i> , 2018, 68, 147-156.	1.8	72
117	Neutrophils: driving progression and poor prognosis in hepatocellular carcinoma?. <i>British Journal of Cancer</i> , 2018, 118, 248-257.	2.9	71
118	Clinical Factors Associated With Liver Stiffness in Hepatitis B e Antigen-Positive Chronic Hepatitis B Patients. <i>Clinical Gastroenterology and Hepatology</i> , 2009, 7, 227-233.	2.4	70
119	Prevalence of the TM6SF2 variant and non-alcoholic fatty liver disease in Chinese. <i>Journal of Hepatology</i> , 2014, 61, 708-709.	1.8	69
120	Putative tumour-suppressor gene DAB2 is frequently down regulated by promoter hypermethylation in nasopharyngeal carcinoma. <i>BMC Cancer</i> , 2010, 10, 253.	1.1	68
121	Chronic hepatitis B in Asia—new insights from the past decade. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 131-137.	1.4	68
122	Detection of ALK Rearrangement by Immunohistochemistry in Lung Adenocarcinoma and the Identification of a Novel EML4-ALK Variant. <i>Journal of Thoracic Oncology</i> , 2013, 8, 883-891.	0.5	67
123	Prognostic Value of Controlled Attenuation Parameter by Transient Elastography. <i>American Journal of Gastroenterology</i> , 2017, 112, 1812-1823.	0.2	67
124	Lymphoepithelioma-like Hepatocellular Carcinoma. <i>American Journal of Surgical Pathology</i> , 2015, 39, 304-312.	2.1	66
125	An inflammatory-CCRK circuitry drives mTORC1-dependent metabolic and immunosuppressive reprogramming in obesity-associated hepatocellular carcinoma. <i>Nature Communications</i> , 2018, 9, 5214.	5.8	66
126	Hypermethylation of the tumor suppressor gene RASSF1A and frequent concomitant loss of heterozygosity at 3p21 in cervical cancers. <i>International Journal of Cancer</i> , 2003, 105, 204-209.	2.3	65

#	ARTICLE	IF	CITATIONS
127	Association Between Anthropometric Parameters and Measurements of Liver Stiffness by Transient Elastography. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 295-302.e3.	2.4	64
128	DNA of Erythroid Origin Is Present in Human Plasma and Informs the Types of Anemia. <i>Clinical Chemistry</i> , 2017, 63, 1614-1623.	1.5	63
129	Interaction of Adipokines and Hepatitis B Virus on Histological Liver Injury in the Chinese. <i>American Journal of Gastroenterology</i> , 2010, 105, 132-138.	0.2	62
130	Inhibition of NOTCH3 signalling significantly enhances sensitivity to cisplatin in EBV-associated nasopharyngeal carcinoma. <i>Journal of Pathology</i> , 2012, 226, 471-481.	2.1	62
131	Assessment of non-alcoholic fatty liver disease using serum total cell death and apoptosis markers. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 36, 1057-1066.	1.9	61
132	Non-invasive algorithm of enhanced liver fibrosis and liver stiffness measurement with transient elastography for advanced liver fibrosis in chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 197-208.	1.9	61
133	Characterization of rare transforming KRAS mutations in sporadic colorectal cancer. <i>Cancer Biology and Therapy</i> , 2014, 15, 768-776.	1.5	61
134	Genetic polymorphisms of adiponectin and tumor necrosis factor- α and nonalcoholic fatty liver disease in Chinese people. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008, 23, 914-921.	1.4	60
135	Liver- and Colon-Specific DNA Methylation Markers in Plasma for Investigation of Colorectal Cancers with or without Liver Metastases. <i>Clinical Chemistry</i> , 2018, 64, 1239-1249.	1.5	60
136	Long-Read RNA Sequencing Identifies Alternative Splice Variants in Hepatocellular Carcinoma and Tumor-Specific Isoforms. <i>Hepatology</i> , 2019, 70, 1011-1025.	3.6	60
137	Serial Transient Elastography Examinations to Monitor Patients With Type 2 Diabetes: A Prospective Cohort Study. <i>Hepatology</i> , 2020, 72, 1230-1241.	3.6	59
138	A selective HDAC8 inhibitor potentiates antitumor immunity and efficacy of immune checkpoint blockade in hepatocellular carcinoma. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	59
139	Yin Yang 1 contributes to gastric carcinogenesis and its nuclear expression correlates with shorter survival in patients with early stage gastric adenocarcinoma. <i>Journal of Translational Medicine</i> , 2014, 12, 80.	1.8	58
140	Significant positive association of endotoxemia with histological severity in 237 patients with non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 175-182.	1.9	58
141	RASAL2 promotes tumor progression through LATS2/YAP1 axis of hippo signaling pathway in colorectal cancer. <i>Molecular Cancer</i> , 2018, 17, 102.	7.9	58
142	Impact of Obesity and Alanine Aminotransferase Levels on the Diagnostic Accuracy for Advanced Liver Fibrosis of Noninvasive Tools in Patients With Nonalcoholic Fatty Liver Disease. <i>American Journal of Gastroenterology</i> , 2019, 114, 916-928.	0.2	57
143	Tenofovir disoproxil fumarate reduces hepatocellular carcinoma, decompensation and death in chronic hepatitis B patients with cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 1037-1048.	1.9	54
144	Risk of hepatitis B surface antigen seroreversion after corticosteroid treatment in patients with previous hepatitis B virus exposure. <i>Journal of Hepatology</i> , 2020, 72, 57-66.	1.8	54

#	ARTICLE	IF	CITATIONS
145	Adverse Effects of Vitamin D Deficiency on Outcomes of Patients With Chronic Hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 783-790.e1.	2.4	52
146	EBV virus-associated lymphoepithelioma-like cholangiocarcinoma: a rare variant of intrahepatic cholangiocarcinoma with favourable outcome. <i>Histopathology</i> , 2014, 65, 674-683.	1.6	51
147	Liver Injury Is Common Among Chronic Abusers of Ketamine. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1759-1762.e1.	2.4	51
148	Profiling of Oncogenic Driver Events in Lung Adenocarcinoma Revealed MET Mutation as Independent Prognostic Factor. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1292-1300.	0.5	51
149	Personalized therapy for hepatocellular carcinoma: Where are we now?. <i>Cancer Treatment Reviews</i> , 2016, 45, 77-86.	3.4	51
150	Repeated Measurements of Hepatitis B Surface Antigen Identify Carriers of Inactive HBV During Long-term Follow-up. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1481-1489.e5.	2.4	51
151	Hepatitis B virus genotype has no impact on hepatitis B e antigen seroconversion after lamivudine treatment. <i>World Journal of Gastroenterology</i> , 2003, 9, 2695.	1.4	50
152	Association of baseline vitamin D levels with clinical parameters and treatment outcomes in chronic hepatitis B. <i>Journal of Hepatology</i> , 2015, 63, 1086-1092.	1.8	49
153	Reassessing the accuracy of PAGE-B-related scores to predict hepatocellular carcinoma development in patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2020, 72, 847-854.	1.8	49
154	Quantitative assessment of fibrosis in liver biopsies from patients with chronic hepatitis B. <i>Liver International</i> , 2004, 24, 611-618.	1.9	48
155	Effects of Diabetes and Glycemic Control on Risk of Hepatocellular Carcinoma After Seroclearance of Hepatitis B Surface Antigen. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 765-773.e2.	2.4	48
156	Strong Immunohistochemical Expression of Vascular Endothelial Growth Factor Predicts Overall Survival in Head and Neck Squamous Cell Carcinoma. <i>Annals of Surgical Oncology</i> , 2007, 14, 3558-3565.	0.7	47
157	Applicability of albumin-bilirubin-based Japan integrated staging score in hepatitis B-associated hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 1766-1772.	1.4	47
158	Incorporating albumin-bilirubin grade into the cancer of the liver Italian program system for hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 221-228.	1.4	47
159	Surrogate End Points and Long-Term Outcome in Patients With Chronic Hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , 2009, 7, 1113-1120.	2.4	46
160	Yin Yang 1-mediated epigenetic silencing of tumour-suppressive microRNAs activates nuclear factor- κ B in hepatocellular carcinoma. <i>Journal of Pathology</i> , 2016, 238, 651-664.	2.1	46
161	Glucuronidation by UGT1A1 Is the Dominant Pathway of the Metabolic Disposition of Belinostat in Liver Cancer Patients. <i>PLoS ONE</i> , 2013, 8, e54522.	1.1	46
162	Application of the combined FibroMeter vibration-controlled transient elastography algorithm in Chinese patients with non-alcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 1363-1369.	1.4	44

#	ARTICLE	IF	CITATIONS
163	EBV-encoded miRNAs target ATM-mediated response in nasopharyngeal carcinoma. <i>Journal of Pathology</i> , 2018, 244, 394-407.	2.1	44
164	Effect of age and disease on taste perception. <i>Journal of Pain and Symptom Management</i> , 2004, 28, 28-34.	0.6	43
165	Clinical utility of plasma Epstein-Barr virus DNA and ERCC1 single nucleotide polymorphism in nasopharyngeal carcinoma. <i>Cancer</i> , 2015, 121, 2720-2729.	2.0	43
166	A subset of breast cancer predisposes to brain metastasis. <i>Medical Molecular Morphology</i> , 2011, 44, 15-20.	0.4	42
167	Assessment of programmed cell death ligand-1 expression by 4 diagnostic assays and its clinicopathological correlation in a large cohort of surgical resected non-small cell lung carcinoma. <i>Modern Pathology</i> , 2018, 31, 1381-1390.	2.9	41
168	No Resistance to Tenofovir Alafenamide Detected through 96 Weeks of Treatment in Patients with Chronic Hepatitis B Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	41
169	Current and Past Infections of HBV Do Not Increase Mortality in Patients With COVID-19. <i>Hepatology</i> , 2021, 74, 1750-1765.	3.6	41
170	Angiotensin-converting enzyme inhibitors prevent liver-related events in nonalcoholic fatty liver disease. <i>Hepatology</i> , 2022, 76, 469-482.	3.6	41
171	Predictors of Treatment Response in Chronic Hepatitis B. <i>Drugs</i> , 2009, 69, 2167-2177.	4.9	40
172	The ATP-binding cassette transporter ABCF1 is a hepatic oncofetal protein that promotes chemoresistance, EMT and cancer stemness in hepatocellular carcinoma. <i>Cancer Letters</i> , 2019, 457, 98-109.	3.2	40
173	Positive Hepatitis B Core Antibody Is Associated With Cirrhosis and Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. <i>American Journal of Gastroenterology</i> , 2020, 115, 867-875.	0.2	40
174	Artificial intelligence in prediction of nonalcoholic fatty liver disease and fibrosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 543-550.	1.4	40
175	Real-world risk score for hepatocellular carcinoma (RWS-HCC): a clinically practical risk predictor for HCC in chronic hepatitis B. <i>Gut</i> , 2016, 65, 887-888.	6.1	39
176	Liver stiffness measurement predicts high-grade post-hepatectomy liver failure: A prospective cohort study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 506-514.	1.4	39
177	Chronic Hepatitis B Increases Liver-Related Mortality of Patients With Acute Hepatitis E: A Territorywide Cohort Study From 2000 to 2016. <i>Clinical Infectious Diseases</i> , 2018, 67, 1278-1284.	2.9	39
178	Systematic evaluation of circulating inflammatory markers for hepatocellular carcinoma. <i>Liver International</i> , 2017, 37, 280-289.	1.9	38
179	Modelling the economic and clinical burden of nonalcoholic steatohepatitis in East Asia: Data from Hong Kong. <i>Hepatology Research</i> , 2020, 50, 1024-1031.	1.8	38
180	Hepatitis Flare During Immunotherapy in Patients With Current or Past Hepatitis B Virus Infection. <i>American Journal of Gastroenterology</i> , 2021, 116, 1274-1283.	0.2	37

#	ARTICLE	IF	CITATIONS
181	Microwave ablation provides better survival than liver resection for hepatocellular carcinoma in patients with borderline liver function: application of ALBI score to patient selection. <i>Hpb</i> , 2018, 20, 546-554.	0.1	36
182	Liver fibrosis progression is uncommon in patients with inactive chronic hepatitis B: A prospective cohort study with paired transient elastography examination. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 1842-1848.	1.4	35
183	Endoscopic ultrasound-guided tissue acquisition with or without macroscopic on-site evaluation: randomized controlled trial. <i>Endoscopy</i> , 2020, 52, 856-863.	1.0	35
184	Characterization of early IgA nephropathy. <i>American Journal of Kidney Diseases</i> , 2000, 36, 703-708.	2.1	34
185	GEFâ€H1 overexpression in hepatocellular carcinoma promotes cell motility via activation of RhoA signalling. <i>Journal of Pathology</i> , 2012, 228, 575-585.	2.1	34
186	Non-alcoholic fatty liver disease: Spectral patterns observed from an in vivo phosphorus magnetic resonance spectroscopy study. <i>Journal of Hepatology</i> , 2014, 60, 809-815.	1.8	34
187	A review of the natural history of chronic hepatitis B in the era of transient elastography. <i>Antiviral Therapy</i> , 2009, 14, 489-499.	0.6	34
188	Outcome of lamivudine resistant hepatitis B virus mutant post-liver transplantation on lamivudine monophylaxis. <i>Clinical Transplantation</i> , 2004, 18, 295-300.	0.8	33
189	Transgenic cyclooxygenase-2 expression and high salt enhanced susceptibility to chemical-induced gastric cancer development in mice. <i>Carcinogenesis</i> , 2008, 29, 1648-1654.	1.3	33
190	Low Risk of Variceal Bleeding in Patients With Cirrhosis After Variceal Screening Stratified by Liver/Spleen Stiffness. <i>Hepatology</i> , 2019, 70, 971-981.	3.6	33
191	Association of genetic variations with NAFLD in lean individuals. <i>Liver International</i> , 2022, 42, 149-160.	1.9	33
192	Long-Term follow-up of Lamivudine Treatment in Patients with Severe Acute Exacerbation of Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B. <i>Antiviral Therapy</i> , 2008, 13, 571-579.	0.6	33
193	Aberrant cholesterol metabolic signaling impairs antitumor immunosurveillance through natural killer T cell dysfunction in obese liver. , 2022, 19, 834-847.		33
194	The anti-diabetic drug exenatide, a glucagon-like peptide-1 receptor agonist, counteracts hepatocarcinogenesis through cAMPâ€PKAâ€EGFRâ€STAT3 axis. <i>Oncogene</i> , 2017, 36, 4135-4149.	2.6	32
195	A prospective study on second-generation colon capsule endoscopy to detect mucosal lesions and disease activity in ulcerative colitis (with video). <i>Gastrointestinal Endoscopy</i> , 2017, 86, 1139-1146.e6.	0.5	32
196	Risk Factors for Active Liver Disease in Hbeag-Negative Chronic Hepatitis B Virusâ€Infected Patients. <i>American Journal of Gastroenterology</i> , 2000, 95, 3547-3551.	0.2	31
197	The effect of caffeine and alcohol consumption on liver fibrosis - a study of 1045 Asian hepatitis B patients using transient elastography. <i>Liver International</i> , 2011, 31, 1047-1053.	1.9	31
198	Measuring spleen stiffness to predict varices in chronic hepatitis B cirrhotic patients with or without receiving non-selective beta-blockers. <i>Journal of Digestive Diseases</i> , 2016, 17, 538-546.	0.7	31

#	ARTICLE	IF	CITATIONS
199	Treatment of advanced hepatocellular carcinoma: immunotherapy from checkpoint blockade to potential of cellular treatment. <i>Translational Gastroenterology and Hepatology</i> , 2018, 3, 89-89.	1.5	30
200	A Retrospective Study on Clinical Features and Prognostic Factors of Biopsy-Proven Primary Biliary Cirrhosis in Chinese Patients. <i>American Journal of Gastroenterology</i> , 2005, 100, 2205-2211.	0.2	29
201	The CCCTC-binding factor (CTCF)-forkhead box protein M1 axis regulates tumour growth and metastasis in hepatocellular carcinoma. <i>Journal of Pathology</i> , 2017, 243, 418-430.	2.1	29
202	A hospital clinic-based survey on traditional Chinese medicine usage among chronic hepatitis B patients. <i>Complementary Therapies in Medicine</i> , 2005, 13, 175-182.	1.3	28
203	Non-invasive assessment of liver fibrosis with transient elastography (FibroScan®): applying the cut-offs of M probe to XL probe. <i>Annals of Hepatology</i> , 2013, 12, 402-412.	0.6	28
204	Targeted hepatitis C screening among exâ€injection drug users in the community. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 116-120.	1.4	28
205	Repeating measurements by transient elastography in nonâ€alcoholic fatty liver disease patients with high liver stiffness. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 241-248.	1.4	28
206	Development of a Novel Inflammation-Based Index for Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2020, 9, 167-181.	4.2	28
207	Higher Estimated Net Endogenous Acid Production May Be Associated with Increased Prevalence of Nonalcoholic Fatty Liver Disease in Chinese Adults in Hong Kong. <i>PLoS ONE</i> , 2015, 10, e0122406.	1.1	28
208	Multimarker Panels for Detection of Early Stage Hepatocellular Carcinoma: A Prospective, Multicenter, Caseâ€Control Study. <i>Hepatology Communications</i> , 2022, 6, 679-691.	2.0	28
209	Progranulin mediates immune evasion of pancreatic ductal adenocarcinoma through regulation of MHC1 expression. <i>Nature Communications</i> , 2022, 13, 156.	5.8	28
210	Two-year lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B: a double-blind, placebo-controlled trial. <i>Antiviral Therapy</i> , 2007, 12, 345-53.	0.6	28
211	Long-Term Lamivudine Treatment is Associated with a Good Maintained Response in Severe Acute Exacerbation of Chronic Hbeag-Negative Hepatitis B. <i>Antiviral Therapy</i> , 2006, 11, 465-471.	0.6	28
212	Virological Response to Different Combination Regimes of Peginterferon Î±-2b and Lamivudine in Hepatitis B e Antigen Positive Chronic Hepatitis B. <i>Antiviral Therapy</i> , 2007, 12, 815-823.	0.6	28
213	Genotype B hepatitis B virus is associated with severe icteric flare-up of chronic hepatitis B virus infection in Hong Kong. <i>American Journal of Gastroenterology</i> , 2002, 97, 2629-2633.	0.2	27
214	Predictors of invasion in needle core biopsies of the breast with ductal carcinoma in situ. <i>Modern Pathology</i> , 2010, 23, 737-742.	2.9	27
215	Significance of hepatitis B virus genotypes and mutations in the development of hepatocellular carcinoma in Asia. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 8-12.	1.4	27
216	Soluble CD163 and mannose receptor associate with chronic hepatitis B activity and fibrosis and decline with treatment. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 484-491.	1.4	27

#	ARTICLE	IF	CITATIONS
217	Quantifying and monitoring fibrosis in non-alcoholic fatty liver disease using dual-photon microscopy. <i>Gut</i> , 2020, 69, 1116-1126.	6.1	27
218	Improving transient elastography performance for detecting hepatitis B cirrhosis. <i>Digestive and Liver Disease</i> , 2012, 44, 61-66.	0.4	26
219	Dysregulated Lysine Acetyltransferase 2B Promotes Inflammatory Bowel Disease Pathogenesis Through Transcriptional Repression of Interleukin-10. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 726-734.	0.6	26
220	Accuracy of Faecal Immunochemical Test to Predict Endoscopic and Histological Healing in Ulcerative Colitis: A Prospective Study Based on Validated Histological Scores. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 1071-1077.	0.6	26
221	Genomic landscape of lymphoepithelioma-like hepatocellular carcinoma. <i>Journal of Pathology</i> , 2019, 249, 166-172.	2.1	26
222	Significantly Lower Case-fatality Ratio of Coronavirus Disease 2019 (COVID-19) than Severe Acute Respiratory Syndrome (SARS) in Hong Kong's A Territory-Wide Cohort Study. <i>Clinical Infectious Diseases</i> , 2021, 72, e466-e475.	2.9	26
223	Risk of Advanced Adenomas in Siblings of Individuals With Advanced Adenomas: A Cross-Sectional Study. <i>Gastroenterology</i> , 2016, 150, 608-616.	0.6	25
224	A Sequential Algorithm Combining ADAPT and Liver Stiffness Can Stage Metabolic-Associated Fatty Liver Disease in Hospital-Based and Primary Care Patients. <i>American Journal of Gastroenterology</i> , 2021, 116, 984-993.	0.2	25
225	Promoter hypermethylation of Death-associated protein-kinase gene associated with advance stage gastric cancer. <i>Oncology Reports</i> , 2005, 13, 937-41.	1.2	25
226	Early Hepatitis B Virus DNA Suppression Can Predict Virologic Response to Peginterferon and Lamivudine Treatment. <i>Clinical Gastroenterology and Hepatology</i> , 2008, 6, 1022-1026.	2.4	24
227	Incorporating Serum Level of Hepatitis B Surface Antigen or Omitting Level of Hepatitis B Virus DNA Does not Affect Calculation of Risk for Hepatocellular Carcinoma in Patients Without Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 461-468.e2.	2.4	24
228	On-Treatment Improvement of MELD Score Reduces Death and Hepatic Events in Patients With Hepatitis B-Related Cirrhosis. <i>American Journal of Gastroenterology</i> , 2018, 113, 1629-1638.	0.2	24
229	Clinical Study of Single-stranded Oligonucleotide RO7062931 in Healthy Volunteers and Patients With Chronic Hepatitis B. <i>Hepatology</i> , 2021, 74, 1795-1808.	3.6	24
230	Risk of liver-related events by age and diabetes duration in patients with diabetes and nonalcoholic fatty liver disease. <i>Hepatology</i> , 2022, 76, 1409-1422.	3.6	24
231	Phylogenetic, Virological, and Clinical Characteristics of Genotype C Hepatitis B Virus with TCC at Codon 15 of the Precore Region. <i>Journal of Clinical Microbiology</i> , 2006, 44, 681-687.	1.8	23
232	Treatment of non-alcoholic steatohepatitis with <i>Scytanthus urinaria</i> : A randomized trial. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 57-62.	1.4	23
233	Ketamine-related cholangiopathy: a retrospective study on clinical and imaging findings. <i>Abdominal Imaging</i> , 2014, 39, 1241-1246.	2.0	23
234	Metabolic syndrome increases cardiovascular events but not hepatic events and death in patients with chronic hepatitis B. <i>Hepatology</i> , 2016, 64, 1507-1517.	3.6	23

#	ARTICLE	IF	CITATIONS
235	Cell cycle-related kinase reprograms the liver immune microenvironment to promote cancer metastasis. <i>Cellular and Molecular Immunology</i> , 2021, 18, 1005-1015.	4.8	23
236	Similarly low risk of hepatocellular carcinoma after either spontaneous or nucleos(t)ide analogue-induced hepatitis B surface antigen loss. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 321-331.	1.9	23
237	Use of Hepatitis B Virus DNA Quantitation To Predict Hepatitis B e Antigen Reversion in Cases of Chronic Hepatitis B. <i>Journal of Clinical Microbiology</i> , 2003, 41, 4793-4795.	1.8	22
238	Evaluation of Impact of Serial Hepatitis B Virus DNA Levels on Development of Hepatocellular Carcinoma. <i>Journal of Clinical Microbiology</i> , 2009, 47, 1830-1836.	1.8	22
239	Reduced <i>CRYL1</i> expression in hepatocellular carcinoma confers cell growth advantages and correlates with adverse patient prognosis. <i>Journal of Pathology</i> , 2010, 220, 348-360.	2.1	22
240	Association of the POU class 2 homeobox 1 gene (POU2F1) with susceptibility to Type 2 diabetes in Chinese populations. <i>Diabetic Medicine</i> , 2010, 27, 1443-1449.	1.2	22
241	Prevention of hepatocellular carcinoma: a concise review of contemporary issues. <i>Annals of Hepatology</i> , 2012, 11, 284-293.	0.6	22
242	Liver fibrosis progression in chronic hepatitis B patients positive for hepatitis B e antigen: A prospective cohort study with paired transient elastography examination. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 1762-1769.	1.4	22
243	A phase 2 study of the efficacy and biomarker on the combination of transarterial chemoembolization and axitinib in the treatment of inoperable hepatocellular carcinoma. <i>Cancer</i> , 2017, 123, 3977-3985.	2.0	22
244	Four-year Outcomes After Cessation of Tenofovir in Immune-tolerant Chronic Hepatitis B Patients. <i>Journal of Clinical Gastroenterology</i> , 2018, 52, 347-352.	1.1	22
245	International validation of the Chinese University Prognostic Index for staging of hepatocellular carcinoma: a joint United Kingdom and Hong Kong study. <i>Chinese Journal of Cancer</i> , 2014, 33, 481-91.	4.9	22
246	MCM7 serves as a prognostic marker in diffuse-type gastric adenocarcinoma and siRNA-mediated knockdown suppresses its oncogenic function. <i>Oncology Reports</i> , 2014, 31, 2071-2078.	1.2	21
247	Steatotic hepatocellular carcinoma: a variant associated with metabolic factors and late tumour relapse. <i>Histopathology</i> , 2016, 69, 971-984.	1.6	21
248	Albumin-bilirubin grade predicts the outcomes of liver resection versus radiofrequency ablation for very early/early stage of hepatocellular carcinoma. <i>Journal of the Royal College of Surgeons of Edinburgh</i> , 2018, 16, 163-170.	0.8	21
249	Performance of Simple Fibrosis Scores in Nonobese Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2843-2845.e2.	2.4	21
250	Metabolic syndrome delays HBsAg seroclearance in Chinese patients with hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 716-726.	1.9	20
251	Evaluation of histological staging systems for primary biliary cirrhosis: correlation with clinical and biochemical factors and significance of pathological parameters in prognostication. <i>Histopathology</i> , 2014, 65, 174-186.	1.6	20
252	Epigenetic silencing of GDF1 disrupts SMAD signaling to reinforce gastric cancer development. <i>Oncogene</i> , 2016, 35, 2133-2144.	2.6	20

#	ARTICLE	IF	CITATIONS
253	Aspirin Reduces the Incidence of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Receiving Oral Nucleos(t)ide Analog. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00324.	1.3	20
254	A phase II clinical study on the efficacy and predictive biomarker of pegylated recombinant arginase on hepatocellular carcinoma. <i>Investigational New Drugs</i> , 2021, 39, 1375-1382.	1.2	20
255	Risk factors for active liver disease in HBeAg-negative chronic hepatitis B virus-infected patients. <i>American Journal of Gastroenterology</i> , 2000, 95, 3547-3551.	0.2	19
256	In vivo appearances of gallbladder carcinoma under magnifying endoscopy and probe-based confocal laser endomicroscopy after endosonographic gallbladder drainage. <i>Endoscopy</i> , 2014, 46, E13-E14.	1.0	19
257	Changing scene in hepatitis B serology interpretation. <i>British Journal of Hospital Medicine</i> , 2002, 63, 16-19.	0.3	18
258	Probability-Based Interpretation of Liver Stiffness Measurement in Untreated Chronic Hepatitis B Patients. <i>Digestive Diseases and Sciences</i> , 2015, 60, 1448-1456.	1.1	18
259	Cross-sectional area of the median nerve at the wrist: Comparison of sonographic, MRI, and cadaveric measurements. <i>Journal of Clinical Ultrasound</i> , 2019, 47, 122-127.	0.4	18
260	Hepatic Decompensation in Cirrhotic Patients Receiving Antiviral Therapy for Chronic Hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1950-1958.e7.	2.4	18
261	Increasing antiviral treatment uptake improves survival in patients with HBV-related HCC. <i>JHEP Reports</i> , 2020, 2, 100152.	2.6	18
262	Laparoscopic Hepatectomy (with or without Robotic Assistance) versus Radiofrequency Ablation as a Minimally Invasive Treatment for Very Early-Stage or Early-Stage Hepatocellular Carcinoma. <i>Digestive Surgery</i> , 2020, 37, 65-71.	0.6	17
263	Thiazolidinediones reduce the risk of hepatocellular carcinoma and hepatic events in diabetic patients with chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2020, 27, 904-914.	1.0	17
264	Promoter hypermethylation of Death-associated protein-kinase gene associated with advance stage gastric cancer. <i>Oncology Reports</i> , 0, , .	1.2	17
265	Second-Trimester Detection of Mowat-Wilson Syndrome Using Comparative Genomic Hybridization Microarray Testing. <i>Obstetrics and Gynecology</i> , 2010, 115, 462-465.	1.2	16
266	Correlation of biomarkers in head and neck squamous cell carcinoma. <i>Otolaryngology - Head and Neck Surgery</i> , 2010, 143, 795-800.	1.1	16
267	Real-life efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir in chronic hepatitis C patients in Hong Kong. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 1230-1233.	1.4	16
268	Increased expression of GATA zinc finger domain containing 1 through gene amplification promotes liver cancer by directly inducing phosphatase of regenerating liver 3. <i>Hepatology</i> , 2018, 67, 2302-2319.	3.6	16
269	Epstein-Barr Virus-Induced Epigenetic Pathogenesis of Viral-Associated Lymphoepithelioma-Like Carcinomas and Natural Killer/T-Cell Lymphomas. <i>Pathogens</i> , 2018, 7, 63.	1.2	16
270	A comparability study of immunohistochemical assays for PD-L1 expression in hepatocellular carcinoma. <i>Modern Pathology</i> , 2019, 32, 1646-1656.	2.9	16

#	ARTICLE	IF	CITATIONS
271	Unresolved issues of immune tolerance in chronic hepatitis B. <i>Journal of Gastroenterology</i> , 2020, 55, 383-389.	2.3	16
272	Risks of AKI and Major Adverse Clinical Outcomes in Patients with Severe Acute Respiratory Syndrome or Coronavirus Disease 2019. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 961-971.	3.0	16
273	HER2 Expression Predicts Improved Survival in Patients with Cervical Node-Positive Head and Neck Squamous Cell Carcinoma. <i>Otolaryngology - Head and Neck Surgery</i> , 2009, 141, 467-473.	1.1	15
274	Multiple modulatory activities of <i>Andrographis paniculata</i> on immune responses and xenograft growth in esophageal cancer preclinical models. <i>Phytomedicine</i> , 2019, 60, 152886.	2.3	15
275	Progressive increase of genetic alteration in urinary bladder cancer by combined allelotyping analysis and comparative genomic hybridization. <i>International Journal of Oncology</i> , 2009, 34, 963-70.	1.4	14
276	Chronic Hepatitis B: A Treatment Update. <i>Seminars in Liver Disease</i> , 2013, 33, 122-129.	1.8	14
277	Targeting ribonucleotide reductase M2 subunit by small interfering RNA exerts anti-oncogenic effects in gastric adenocarcinoma. <i>Oncology Reports</i> , 2014, 31, 2579-2586.	1.2	14
278	Applicability of BALAD score in prognostication of hepatitis B-related hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 1529-1535.	1.4	14
279	Improvement in enhanced liver fibrosis score and liver stiffness measurement reflects lower risk of hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1509-1517.	1.9	14
280	Serum fibrosis index-based risk score predicts hepatocellular carcinoma in untreated patients with chronic hepatitis B. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 499-509.	4.5	14
281	A review of the natural history of chronic hepatitis B in the era of transient elastography. <i>Antiviral Therapy</i> , 2009, 14, 489-99.	0.6	14
282	Granulin epithelin precursor promotes colorectal carcinogenesis by activating MARK/ERK pathway. <i>Journal of Translational Medicine</i> , 2018, 16, 150.	1.8	13
283	Change in treatment paradigm in people who previously injected drugs with chronic hepatitis C in the era of direct-acting antiviral therapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 1641-1647.	1.4	13
284	Unique molecular characteristics of NAFLD-associated liver cancer accentuate β -catenin/TNFRSF19-mediated immune evasion. <i>Journal of Hepatology</i> , 2022, 77, 410-423.	1.8	13
285	Congenital systemic Langerhans cell histiocytosis presenting as hydrops fetalis. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2005, 94, 1843-1847.	0.7	12
286	Serum hepatitis B surface antigen kinetics in severe reactivation of hepatitis e antigen negative chronic hepatitis B patients receiving nucleos(t)ide analogues. <i>Antiviral Therapy</i> , 2013, 18, 979-986.	0.6	12
287	Noninvasive assessments of liver fibrosis with transient elastography and Hui index predict survival in patients with chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 582-590.	1.4	12
288	Virus and Host Testing to Manage Chronic Hepatitis B. <i>Clinical Infectious Diseases</i> , 2016, 62, S298-S305.	2.9	12

#	ARTICLE	IF	CITATIONS
289	EXOSC4 functions as a potential oncogene in development and progression of colorectal cancer. <i>Molecular Carcinogenesis</i> , 2018, 57, 1780-1791.	1.3	12
290	Negligible HCC risk during stringently defined untreated immune-tolerant phase of chronic hepatitis B. <i>European Journal of Internal Medicine</i> , 2021, 84, 68-73.	1.0	12
291	A prospective 5-year study on the use of transient elastography to monitor the improvement of non-alcoholic fatty liver disease following bariatric surgery. <i>Scientific Reports</i> , 2021, 11, 5416.	1.6	12
292	U-shaped relationship between urea level and hepatic decompensation in chronic liver diseases. <i>Clinical and Molecular Hepatology</i> , 2022, 28, 77-90.	4.5	12
293	Novel machine learning models outperform risk scores in predicting hepatocellular carcinoma in patients with chronic viral hepatitis. <i>JHEP Reports</i> , 2022, 4, 100441.	2.6	12
294	Antiviral therapy for chronic hepatitis B: Challenges in Hong Kong. <i>Journal of Hepatology</i> , 2009, 51, 1088-1090.	1.8	11
295	Primary perivascular epithelioid cell tumour (PEComa) of the urinary bladder. <i>Pathology</i> , 2011, 43, 746-749.	0.3	11
296	A concurrent primary hepatic MALT lymphoma and hepatocellular carcinoma. <i>Pathology</i> , 2015, 47, 178-181.	0.3	11
297	Cost Effectiveness of Response-Guided Therapy With Peginterferon in the Treatment of Chronic Hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 377-385.e5.	2.4	11
298	A Pancreatic Mass With Multiple Hepatic Lesions. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, e3-e4.	2.4	11
299	Validating the ALBI grade: Its current and future use in HCC prognostication. <i>Journal of Hepatology</i> , 2017, 66, 661-663.	1.8	11
300	EBV-encoded miRNAs can sensitize nasopharyngeal carcinoma to chemotherapeutic drugs by targeting BRCA1. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 13523-13535.	1.6	11
301	Extramedullary Nasal Plasmacytoma – An Unusual Clinical Entity. <i>Ear, Nose and Throat Journal</i> , 1996, 75, 171-173.	0.4	10
302	Impact of diabetes mellitus and hepatitis B virus coinfection on patients with chronic hepatitis C: A territory-wide cohort study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 934-941.	1.4	10
303	Virtual multiplex immunohistochemistry: Application on cell block of effusion and aspiration cytology. <i>Diagnostic Cytopathology</i> , 2020, 48, 417-423.	0.5	10
304	SARS-CoV-2 Viral Persistence Based on Cycle Threshold Value and Liver Injury in Patients With COVID-19. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab205.	0.4	10
305	Malignant pigmented clear cell epithelioid cell tumor (PEComa) in an adolescent boy with widespread metastases: a rare entity in this age group. <i>Pediatric Radiology</i> , 2011, 41, 1587-1590.	1.1	9
306	Novel therapeutic targets and predictive markers for hepatocellular carcinoma. <i>Expert Opinion on Therapeutic Targets</i> , 2015, 19, 973-983.	1.5	9

#	ARTICLE	IF	CITATIONS
307	Association Between Serum Folate Level and Toxicity of Capecitabine During Treatment for Colorectal Cancer. <i>Oncologist</i> , 2018, 23, 1436-1445.	1.9	9
308	Peginterferon Alfa-2a (40 kD) Stopping Rules in Chronic Hepatitis B: A Systematic Review and Meta-Analysis of Individual Participant Data. <i>Antiviral Therapy</i> , 2019, 24, 133-140.	0.6	9
309	Receptor tyrosine kinase fusions act as a significant alternative driver of the serrated pathway in colorectal cancer development. <i>Journal of Pathology</i> , 2020, 251, 74-86.	2.1	9
310	Colonoscopy and Risk of Colorectal Cancer in Patients With Nonalcoholic Fatty Liver Disease: A Retrospective Territory-Wide Cohort Study. <i>Hepatology Communications</i> , 2021, 5, 1212-1223.	2.0	9
311	Familial extrarenal Wilms tumor. <i>Journal of Pediatric Surgery</i> , 2007, 42, 1826-1830.	0.8	8
312	A sensitive and specific liquid chromatography-tandem mass spectrometric method for determination of belinostat in plasma from liver cancer patients. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2010, 878, 2409-2414.	1.2	8
313	EUS-guided alcohol injection of pancreatic neuroendocrine tumor. <i>Gastrointestinal Endoscopy</i> , 2015, 82, 167.	0.5	8
314	Long-term lamivudine treatment is associated with a good maintained response in severe acute exacerbation of chronic HBeAg-negative hepatitis B. <i>Antiviral Therapy</i> , 2006, 11, 465-71.	0.6	8
315	Virological response to different combination regimes of peginterferon alpha-2b and lamivudine in hepatitis B e antigen positive chronic hepatitis B. <i>Antiviral Therapy</i> , 2007, 12, 815-23.	0.6	8
316	Antiviral Drug Resistance Testing in Patients with Chronic Hepatitis B. <i>Digestive Diseases and Sciences</i> , 2012, 57, 221-231.	1.1	7
317	Peginterferon therapy for chronic hepatitis B: one size fits all?. <i>Gut</i> , 2013, 62, 185-187.	6.1	7
318	An Uncommon Insertion Mutation in Exon 19 of EGFR Showed Stable Disease after TKI Treatment. <i>Journal of Thoracic Oncology</i> , 2013, 8, e107-e108.	0.5	7
319	Impact of IL28B and PNPLA3 polymorphisms on treatment outcomes in patients infected with genotype 6 hepatitis C virus. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 1040-1048.	1.4	7
320	Impact of Weight Loss During Chemotherapy in Chinese Patients with Unresectable Pancreatic Cancer. <i>Nutrition and Cancer</i> , 2019, 71, 954-970.	0.9	7
321	Endoscopic ultrasound of pancreatic lesions. <i>Journal of Visualized Surgery</i> , 2016, 2, 119-119.	0.2	6
322	No association between IFNL3 (IL28B) genotype and response to peginterferon alfa-2a in HBeAg-positive or -negative chronic hepatitis B. <i>PLoS ONE</i> , 2018, 13, e0199198.	1.1	6
323	Macromolecular proton fraction mapping based on spin-echo magnetic resonance imaging. <i>Magnetic Resonance in Medicine</i> , 2020, 84, 3157-3171.	1.9	6
324	High incidence of hepatocellular carcinoma and cirrhotic complications in patients with psychiatric illness: a territory-wide cohort study. <i>BMC Gastroenterology</i> , 2020, 20, 128.	0.8	6

#	ARTICLE	IF	CITATIONS
325	Liver stiffness measurement predicts short-term and long-term outcomes in patients with hepatocellular carcinoma after curative liver resection. <i>Journal of the Royal College of Surgeons of Edinburgh</i> , 2022, 20, 78-84.	0.8	6
326	EUS-guided transduodenal biliary drainage. <i>Gastrointestinal Endoscopy</i> , 2010, 72, 186-187.	0.5	5
327	Benign epithelioid schwannoma of intraparotid facial nerve. <i>Pathology</i> , 2011, 43, 280-282.	0.3	5
328	45 YEAR OLD MAN WITH A PINEAL REGION TUMOR FOR OVER 15 YEARS. <i>Brain Pathology</i> , 2012, 22, 255-258.	2.1	5
329	Irreversible Electroporation of the Femoral Neurovascular Bundle: Imaging and Histologic Evaluation in a Swine Model. <i>Journal of Vascular and Interventional Radiology</i> , 2015, 26, 1212-1220.e1.	0.2	5
330	Topical Application of Mesenchymal Stromal Cells Ameliorated Liver Parenchyma Damage After Ischemia-Reperfusion Injury in an Animal Model. <i>Transplantation Direct</i> , 2017, 3, e160.	0.8	5
331	Primary hepatic gastrointestinal stromal tumor presented with rupture. <i>Hepatobiliary Surgery and Nutrition</i> , 2017, 6, 65-66.	0.7	5
332	Genetic variation in ABCB5 associates with risk of hepatocellular carcinoma. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 10705-10713.	1.6	5
333	Hepatitis B Core-Related Antigen: From Virology to Clinical Application. <i>Seminars in Liver Disease</i> , 2021, 41, 182-190.	1.8	5
334	Non-Hodgkin's Lymphoma of the Knee: A Case Report. <i>Iranian Journal of Radiology</i> , 2015, 12, e7583.	0.1	5
335	Reliability of the nonalcoholic steatohepatitis clinical research network and steatosis activity fibrosis histological scoring systems. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, 37, 1131-1138.	1.4	5
336	Tenofovir alafenamide is associated with improved alanine aminotransferase and renal safety compared to tenofovir disoproxil fumarate. <i>Journal of Medical Virology</i> , 2022, 94, 4440-4448.	2.5	5
337	Is transient elastography inaccurate in chronic hepatitis B and non-alcoholic fatty liver disease?. <i>Journal of Hepatology</i> , 2011, 55, 497.	1.8	4
338	Should all patients with nonalcoholic fatty liver disease undergo oral glucose tolerance test?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 419-420.	1.4	4
339	Treatment of hepatitis C virus infection in patients with CKD. <i>Nature Reviews Nephrology</i> , 2016, 12, 5-6.	4.1	4
340	Ablative Chemoembolization for Hepatocellular Carcinoma: A Prospective Phase I Case-Control Comparison with Conventional Chemoembolization. <i>Radiology</i> , 2018, 287, 340-348.	3.6	4
341	Novel biomarkers GEP/ABCB5 regulate response to adjuvant transarterial chemoembolization after curative hepatectomy for hepatocellular carcinoma. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2018, 17, 524-530.	0.6	4
342	Updates of pancreatic neuroendocrine neoplasm in the 2017 World Health Organization classification. <i>Surgical Practice</i> , 2019, 23, 42-47.	0.1	4

#	ARTICLE	IF	CITATIONS
343	Factors associated with improvement in MELD score after antiviral treatment in patients with chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1610-1618.	1.4	4
344	Reply:. <i>Hepatology</i> , 2009, 50, 2049-2050.	3.6	3
345	Responseâ€guided therapy by hepatitis B surface antigen level for peginterferon therapy: What is next?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 420-421.	1.4	3
346	Mechanism and Natural Course of Tumor Involution in Hepatocellular Carcinoma Following Transarterial Ethanol Ablation. <i>CardioVascular and Interventional Radiology</i> , 2016, 39, 1136-1143.	0.9	3
347	Reply to: Correspondence concerning â€œDevelopment of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resectionâ€. <i>Journal of Hepatology</i> , 2019, 70, 573-574.	1.8	3
348	Alpha-Fetoprotein as a Biomarker in Hepatocellular Carcinoma: Focus on Its Role in Composition of Tumor Staging Systems and Monitoring of Treatment Response. <i>Biomarkers in Disease</i> , 2017, , 623-635.	0.0	3
349	Virodynamic Predictors of Response to Pegylated Interferon and Lamivudine Combination Treatment of Hepatitis B e Antigen-Positive Chronic Hepatitis B. <i>Antiviral Therapy</i> , 2008, 13, 1029-1037.	0.6	3
350	984 COMBINATION OF THE MEDIAN AND VARIABILITY OF LIVER STIFFNESS MEASUREMENTS BY TRANSIENT ELASTOGRAPHY IMPROVES THE ACCURACY OF DIAGNOSING ADVANCED FIBROSIS IN NONALCOHOLIC FATTY LIVER DISEASE. <i>Journal of Hepatology</i> , 2008, 48, S367.	1.8	2
351	Renal myxoid tumour of uncertain malignant potential. <i>Pathology</i> , 2011, 43, 287-289.	0.3	2
352	Two are better than one: noninvasive assessment of liver fibrosis in nonalcoholic fatty liver disease. <i>Hepatology International</i> , 2015, 9, 481-483.	1.9	2
353	HHV8 genotype study in an HIV+ patient with concurrent Kaposi sarcoma and extracavitary primary effusion lymphoma. <i>Journal of Clinical Pathology</i> , 2017, 70, 814-816.	1.0	2
354	Peptostreptococcus Anaerobius Induces Intracellular Cholesterol Biosynthesis in Colon Cells to Induce Proliferation and Causes Dysplasia in Mice. <i>Gastroenterology</i> , 2017, 152, S1010.	0.6	2
355	Towards finite oral antiviral treatment for chronic hepatitis B. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 260-262.	3.7	2
356	Reply. <i>Hepatology</i> , 2016, 64, 685-686.	3.6	1
357	Fecal Immunochemical Test Predicts Histological Healing in Ulcerative Colitis: A Prospective Study Using the Geboes Score and Nancy Index. <i>Gastroenterology</i> , 2017, 152, S209.	0.6	1
358	Serial combination of noninvasive tools improves the diagnostic accuracy of severe liver fibrosis in patients with nonalcoholic fatty liver disease. <i>Digestive and Liver Disease</i> , 2017, 49, e2.	0.4	1
359	Impact of Non-alcoholic Fatty Liver Disease on Chronic Hepatitis B Infection. <i>Current Hepatology Reports</i> , 2017, 16, 97-104.	0.4	1
360	IDDF2018-ABS-0107â€...Efficacy and safety of TENOFOVIR ALAFENAMIDE (TAF) at 96 weeks in chronic HBV (CHB) patients with risk factors for use of TENOFOVIR DISOPROXIL FUMARATE (TDF). , 2018, , .		1

#	ARTICLE	IF	CITATIONS
361	PS-201-External validation in NAFLD cohorts of the FibroScan-based FAST score combining liver stiffness, controlled attenuation parameter and AST to identify patients with active NASH (NAS ≥ 4) and significant fibrosis (F ≥ 2). <i>Journal of Hepatology</i> , 2019, 70, e134-e135.	1.8	1
362	En bloc transdiaphragmatic lung resection for locally advanced hepatocellular carcinoma: a case report. <i>Journal of Surgical Case Reports</i> , 2020, 2020, rjaa084.	0.2	1
363	Letter to the Editor: Use of Pregenomic Hepatitis B Virus RNA and Hepatitis B Core-Related Antigen to Predict Cure of Hepatitis B Virus Infection. <i>Hepatology</i> , 2021, 73, 870-870.	3.6	1
364	Sodium-glucose cotransporter 2 inhibitors reduce hepatic events in diabetic patients with chronic hepatitis B. <i>GastroHep</i> , 2021, 3, 261-269.	0.3	1
365	Single-nucleotide polymorphism (SNP) of excision repair cross complementation group 1 (ERCC1) in nasopharynx cancer (NPC): A companion biomarker study to Hong Kong NPC Study Group 0502 trial.. <i>Journal of Clinical Oncology</i> , 2014, 32, 6029-6029.	0.8	1
366	The association between serum folate level and toxicity of capecitabine.. <i>Journal of Clinical Oncology</i> , 2016, 34, 3566-3566.	0.8	1
367	A study on thromboembolism of patients with pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 262-262.	0.8	1
368	CD133 and EpCAM as Biomarkers in Liver Diseases. <i>Biomarkers in Disease</i> , 2017, , 349-372.	0.0	1
369	Abstract 4563: PD-L1 expression associated with treatment responses in colorectal cancer patients with XELOX/FOLFOX chemotherapy: Potential of checkpoint blockage and natural killer cell-based immunotherapy. , 2018, , .		1
370	Letter: systematic review with meta-analysis on the impact of functional cure on clinical outcomes in patients with chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 616-617.	1.9	1
371	Molecular virology and drug resistance in antiviral therapy of chronic hepatitis B. <i>Current Hepatitis Reports</i> , 2005, 4, 27-33.	0.3	0
372	Fine needle aspiration cytology of breast cancer in women aged 70 years and older. <i>Pathology</i> , 2008, 40, 573-579.	0.3	0
373	Metabolic syndrome and chronic hepatitis B: is the evidence enough?. <i>Gut</i> , 2010, 59, 277.1-277.	6.1	0
374	Case report and a review of the literature of two patients with gastric MALToma and pulmonary metastasis. <i>Surgical Practice</i> , 2013, 17, 28-30.	0.1	0
375	Case of hepatocellular carcinoma with multicentric Castleman's disease. <i>Surgical Practice</i> , 2014, 18, 154-155.	0.1	0
376	A Rare Tumor of the Common Hepatic Duct Causing Biliary Obstruction. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, e29-e30.	2.4	0
377	A Rare Cause of Protein-Losing Enteropathy. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, e49-e50.	2.4	0
378	Development of Serum DHCR24 Antibody as a Marker for Hepatocellular Carcinoma: The End of the Beginning. <i>EBioMedicine</i> , 2015, 2, 497-498.	2.7	0

#	ARTICLE	IF	CITATIONS
379	Reply. Hepatology, 2016, 64, 1820-1821.	3.6	0
380	MET DNA Alterations in NSCLCâ€”Reply. Clinical Cancer Research, 2016, 22, 3699-3699.	3.2	0
381	A Rare Cause of Ischemic Colitis. Clinical Gastroenterology and Hepatology, 2016, 14, e109-e110.	2.4	0
382	Comments on â€œProposal and validation of a new model to estimate survival for hepatocellular carcinoma patientsâ€• European Journal of Cancer, 2016, 68, 203-205.	1.3	0
383	Reply to: â€œSerum HBsAg kinetics in clinical predictionâ€• Journal of Hepatology, 2017, 67, 193-194.	1.8	0
384	GATAD1 Promotes Hepatocellular Carcinogenesis through Directly Inducing PTP4A3 and Activating Akt Pathway. Gastroenterology, 2017, 152, S1182.	0.6	0
385	Non-invasive Assessment of Liver Disease. , 2018, , 163-179.		0
386	Reply to: â€œRisk factors of hepatocellular carcinoma after hepatitis B surface antigen seroclearanceâ€• Journal of Hepatology, 2018, 68, 208-209.	1.8	0
387	IDDF2018-ABS-0058â€…Early normalisation of alanine aminotransferase (alt) after nucleos(t)ide analogue treatment reduces the risk of hepatocellular carcinoma (hcc) in patients with chronic hepatitis b â€œ a territory-wide study of 21,182 subjects. , 2018, , .		0
388	IDDF2018-ABS-0106â€…Tenofovir alafenamide (taf) compared with tenofovir disoproxil fumarate (tdf) in patients with chronic hbv: week 96 efficacy and safety results in chinese patients enrolled in 2 global phase 3 studies. , 2018, , .		0
389	Reply to: â€œNAFLD and beneficial effects of lifestyle intervention: Defining the meat of the matterâ€• Journal of Hepatology, 2019, 70, 1304.	1.8	0
390	IDDF2019-ABS-0199â€…The risk of metabolic acidosis in diabetic patients with different severity of chronic hepatitis B-related cirrhosis and renal impairment. , 2019, , .		0
391	IDDF2019-ABS-0325â€…Superior efficacy and long-term survival benefit of HDAC8 and PD-L1 co-blockade in liver cancer immunotherapy. , 2019, , .		0
392	IDDF2019-ABS-0174â€…Targeting monocyte-intrinsic enhancer reprogramming improves immunotherapy efficacy in hepatocellular carcinoma. , 2019, , .		0
393	Reply to: â€œHepatocellular carcinoma risk stratification in HBV cirrhosis: Time to turn the pageâ€• Journal of Hepatology, 2020, 73, 729-730.	1.8	0
394	Debate settled for elevated alanine aminotransferase in hepatitis B?. Lancet Infectious Diseases, The, 2021, 21, 750-751.	4.6	0
395	IDDF2021-ABS-0122â€…No association between proton-pump inhibitor use and adverse clinical outcomes of COVID-19: a territory-wide cohort study of 8,675 patients. , 2021, , .		0
396	Abstract 4127: MiR-183/96/182 cluster confers cell motile advantages in hepatocellular carcinoma. , 2012, , .		0

#	ARTICLE	IF	CITATIONS
397	Abstract 1245: Reactivation of growth/differentiation factor 1 contributes to the chemopreventive effect of 5-aza-2-deoxycytidine in gastric cancer. , 2014, , .		0
398	CD133 and EpCAM as Biomarkers in Liver Diseases. Exposure and Health, 2015, , 1-24.	2.8	0
399	A phase II clinical trial on combined axitinib and transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC): Final results and evaluation of clinical predictor for response.. Journal of Clinical Oncology, 2015, 33, 4073-4073.	0.8	0
400	Alpha-Fetoprotein as a Biomarker in Hepatocellular Carcinoma: Focus on Its Role in Composition of Tumor Staging Systems and Monitoring of Treatment Response. Biomarkers in Disease, 2016, , 1-13.	0.0	0
401	Clinical Application, Performance, and Common Pitfalls of Ultrasound-guided Pleural Biopsy: Our Local Experience. Hong Kong Journal of Radiology, 0, , 103-110.	0.1	0
402	A novel and validated inflammation-integrated prognostic model for hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2017, 35, e15679-e15679.	0.8	0
403	Hepatic adverse events during treatment with immune checkpoint inhibitors (ICI) in cancer patients: A territory-wide patient cohort study.. Journal of Clinical Oncology, 2020, 38, 508-508.	0.8	0
404	IDDF2020-ABS-0200â€¦Impact of rising prevalence of metabolic comorbidities on accuracy of hepatocellular carcinoma risk score in chronic hepatitis B patients receiving antiviral therapy: A territory-wide cohort of 31,953 treated patients. , 2020, , .		0
405	Recognising the clinically significant macrotrabecular massive variant of hepatocellular carcinoma. Singapore Medical Journal, 2022, , .	0.3	0
406	Use of Proton-Pump Inhibitor Is Not Associated with Adverse Clinical Outcomes in COVID-19 Patients: A Territory-Wide Cohort Study. GastroHep, 2022, 2022, 1-13.	0.3	0